A Focus in Hematologic Malignancies

Hematologic malignancies are forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancers include acute and chronic leukemias, lymphomas, multiple myeloma and myelodysplastic syndromes.  

Karyopharm continues to support research and clinical development across many different types of hematologic cancer, with the most extensive research completed in patients with multiple myeloma and diffuse large B-cell lymphoma (DLBCL).


Multiple Myeloma

Multiple myeloma is a blood cancer that develops in the bone marrow, the soft, spongy tissue found in the center of many bones where blood cells are produced.

Diffuse Large B-Cell Lymphoma of Stomach


Lymphoma is a blood cancer that develops in cells of the immune system called lymphocytes.

A Focus in Solid Tumors

Solid tumor cancers typically describe an abnormal mass of tissue and are named for the type of cells where they originate.  For example, a tumor that arises in the brain, is called a brain tumor. When cancer cells break away from the original (primary) tumor and form a new tumor in other organs or tissues of the body, this is known as a metastasis.  Despite its new location, the metastatic tumor is the same type of cancer as the primary tumor.

Karyopharm is currently conducting a number of clinical studies with its investigational medicines in a variety of solid tumor indications.  The most advanced study is in patients with liposarcoma, which is a rare form of cancer that arises in a patient’s fat cells. Most liposarcomas tend to grow slowly, but some may grow quickly and spread to nearby tissue or to other parts of the body.

Additionally, Karyopharm’s investigational products are being studied in patients with other forms of solid tumors including endometrial cancer, ovarian cancer, brain cancer (specifically gliomas), colorectal cancer, and lung cancer.

Clinical Trials

Clinical Trials

Learn more about ongoing clinical trials of Karyopharm investigational medicines.